Table 2.
RNA silencers in development
| Agent | Stage of development | Clinical trial number | |
|---|---|---|---|
| siRNA | ARC-520 | Phase II | Discontinued |
| ARB-1467 | Phase II | Discontinued | |
| AB-729 | Phase II | NCT04820686 | |
| RG-6346 | Phase II | NCT03772249 | |
| VIR-2218 | Phase II | NCT03672188 | |
| JNJ-3989 | Phase II | NCT04129554 | |
| ALG-125755 | Preclinical | Planned to enter clinical trials in 2022 | |
| ALG-125918 | Preclinical | / | |
| ASO | Bepirovirsen | Phase II | NCT02981602 |
| GSK3389404 | Phase II | NCT03020745 | |
| RO7062931 | Phase I | NCT03038113 | |
| ALG-020572 | Phase I | NCT05001022 | |
| Combination therapy | AB-729 (siRNA) + capsid assembly modulator (vebicorvir) | Phase II | NCT04820686 |
| RG-6346 (siRNA) + pegylated interferon | Phase II | NCT04225715 | |
| RG-6346 (siRNA) + capsid assembly modulator (RO7049389) | Phase II | NCT04225715 | |
| RG-6346(siRNA)+toll-likereceptoragonist(RO7020531) | Phase II | NCT04225715 | |
| VIR-2218 (siRNA) + pegylated interferon | Phase II | NCT04412863 | |
| JNJ-3989 (siRNA) + capsid assembly modulator (JNJ-6379) | Phase II | NCT03982186 | |
| GSK3389404 (ASO) + pegylated interferon | Phase II | NCT04676724 | |
| ALG-125755 (siRNA) + ALG-020572 (ASO) | Preclinical | / | |
| ALG-125903 (siRNA) + ALG-020579 (ASO) + ALG-010133 (HBsAg transport inhibiting oligonucleotide polymer) | Preclinical | / |
siRNA, small-interfering RNA; ASO, antisense oligonucleotide; HBsAg, hepatitis B surface antigen.